Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 9th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 23rd. Jefferies Group LLC reissued a “buy” rating and set a $7.00 price target (down previously from $8.00) on shares of Dicerna Pharmaceuticals in a research report on Sunday, April 2nd. Finally, Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 24th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $5.88.

Dicerna Pharmaceuticals (NASDAQ DRNA) opened at 4.13 on Friday. The company’s 50-day moving average is $3.18 and its 200-day moving average is $3.02. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10. The company’s market cap is $85.88 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.08 million. On average, analysts anticipate that Dicerna Pharmaceuticals will post ($2.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/22/dicerna-pharmaceuticals-inc-nasdaqdrna-upgraded-by-valuengine-to-hold.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Palo Alto Investors LLC raised its position in shares of Dicerna Pharmaceuticals by 204.2% in the first quarter. Palo Alto Investors LLC now owns 481,519 shares of the biopharmaceutical company’s stock valued at $1,637,000 after buying an additional 323,240 shares during the period. Renaissance Technologies LLC raised its position in shares of Dicerna Pharmaceuticals by 2.4% in the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock valued at $1,423,000 after buying an additional 9,818 shares during the period. UBS Group AG raised its position in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the period. Sabby Management LLC raised its position in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 100,000 shares during the period. Finally, Paloma Partners Management Co raised its position in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 53,131 shares during the period. Institutional investors and hedge funds own 55.82% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.